Semaglutide, a glucagon-like peptide-1 receptor agonist, used for Type 2 diabetes mellitus and more recently for weight loss, often causes gastrointestinal adverse effects such as delayed gastric emptying and abdominal discomfort. Current literature has not described an associated case of gastric pneumatosis with semaglutide use. We report a 61-year-old man on semaglutide for 9 months with gastric pneumatosis. Symptoms resolved on discontinuation. Clinicians should be vigilant for significant gastrointestinal adverse effects, including pneumatosis with semaglutide use.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11671069 | PMC |
| http://dx.doi.org/10.14309/crj.0000000000001579 | DOI Listing |
Publication Analysis
Top Keywords
gastric pneumatosis
12
pneumatosis semaglutide
12
gastrointestinal adverse
8
adverse effects
8
semaglutide-associated gastric
4
pneumatosis
4
semaglutide
4
semaglutide glucagon-like
4
glucagon-like peptide-1
4
peptide-1 receptor
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!